Citigroup Inc. Reaffirms “Buy” Rating for Shire PLC (SHP)
Other research analysts have also recently issued reports about the stock. Deutsche Bank AG reiterated a buy rating and set a GBX 5,600 ($73.10) price target on shares of Shire PLC in a research report on Monday, June 13th. Royal Bank Of Canada restated an outperform rating on shares of Shire PLC in a report on Friday, July 22nd. JPMorgan Chase & Co. restated an overweight rating and issued a GBX 6,300 ($82.23) target price on shares of Shire PLC in a report on Tuesday, August 16th. Jefferies Group raised their target price on shares of Shire PLC from GBX 6,050 ($78.97) to GBX 6,600 ($86.15) and gave the stock a buy rating in a report on Wednesday, August 3rd. Finally, Credit Suisse Group AG raised their target price on shares of Shire PLC from GBX 5,000 ($65.27) to GBX 5,200 ($67.88) and gave the stock an outperform rating in a report on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of GBX 5,828 ($76.07).
Shire PLC (LON:SHP) opened at 5018.00 on Tuesday. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00. The firm’s market cap is GBX 34.26 billion. The firm’s 50-day moving average is GBX 4,983.22 and its 200 day moving average is GBX 4,511.67.
The firm also recently announced a dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 8th will be given a GBX 3.51 ($0.05) dividend. This represents a yield of 0.07%. The ex-dividend date is Thursday, September 8th.
In other Shire PLC news, insider Dominic Blakemore bought 133 shares of the firm’s stock in a transaction on Friday, September 30th. The stock was acquired at an average price of GBX 5,010 ($65.40) per share, with a total value of £6,663.30 ($8,697.69).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.